Johnson & Johnson Might Pay $1.8 Billion for Risperdal Claims
Pharmaceutical giant Johnson & Johnson may have to pay over $1.8 billion to settle claims related to its marketing of its blockbuster antipsychotic drug Risperdal. The drug was once Johnson & Johnson’s best-selling drug, generating over $24 billion in 2003. Risperdal was approved by the Food and Drug Administration to treat psychotic disorders, but the…
